Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18937634 | 0.87 | MAPK1 (0.54) | MAPK1RIPK1JAK2JAK1JAK3 | |
| SCHEMBL12810052 | 0.81 | MAPK1 (0.44) | MAPK1RIPK1APPPDE10AAXL | |
| SCHEMBL18937802 | 0.78 | PDE10A (0.32) | JAK2PDE10A | |
| SCHEMBL21335023 | 0.75 | KDM4E (0.33) | — | |
| SCHEMBL18430380 | 0.74 | AXL (0.37) | MAPK1APPAXLNUDT1 | |
| SCHEMBL21025526 | 0.74 | MAPK1 (0.44) | MAPK1RIPK1APPAXLNUDT1 | |
| SCHEMBL9968617 | 0.72 | PDE10A (0.62) | PDE10A | |
| SCHEMBL18937797 | 0.71 | KDM4E (0.37) | — | |
| SCHEMBL10141177 | 0.71 | MAPK1 (0.48) | MAPK1RIPK1APPJAK2JAK1 | |
| SCHEMBL12847281 | 0.71 | MAPK1 (0.71) | MAPK1RIPK1APPAXLNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | MAPK1 97/4885RIPK1 492/4885APP 4662/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | MAPK1 97/4885RIPK1 492/4885APP 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.